GlassScriptPhysician profile
Angela Lebeter
NPI 1144895418
$851.09
in general payments reported to CMS, 2019-2025
14 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $88.08 · 2022: $111 · 2023: $316 · 2024: $227 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $651.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $192.25 | 2021-2025 | Otezla, Repatha, Repatha |
| Mirati Therapeutics, INC. | $120.57 | 2023 | Krazati |
| E.R. Squibb & Sons, L.L.C. | $116.37 | 2023 | Reblozyl |
| Inari Medical, INC. | $94.48 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Xeris Pharmaceuticals, INC. | $64.88 | 2023-2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.28 | 2022 | |
| Abbvie INC. | $50.73 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.60 | 2021 | |
| Novo Nordisk INC | $29.30 | 2025 | |
| Lilly USA, LLC | $25.00 | 2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $18.01 | 2024 | |
| Idorsia Pharmaceuticals US INC | $15.44 | 2024 | Quviviq |
| Dexcom, INC. | $13.25 | 2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Lebeter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.